[go: up one dir, main page]

DE60118571D1 - Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten - Google Patents

Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten

Info

Publication number
DE60118571D1
DE60118571D1 DE60118571T DE60118571T DE60118571D1 DE 60118571 D1 DE60118571 D1 DE 60118571D1 DE 60118571 T DE60118571 T DE 60118571T DE 60118571 T DE60118571 T DE 60118571T DE 60118571 D1 DE60118571 D1 DE 60118571D1
Authority
DE
Germany
Prior art keywords
treatment
pharmaceutical compositions
topoisomerase inhibitors
cancer containing
containing thalidomide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60118571T
Other languages
English (en)
Other versions
DE60118571T2 (de
Inventor
B Zeldis
Andrew Zeitlin
Sol Barer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of DE60118571D1 publication Critical patent/DE60118571D1/de
Application granted granted Critical
Publication of DE60118571T2 publication Critical patent/DE60118571T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60118571T 2000-05-15 2001-05-10 Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten Expired - Lifetime DE60118571T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20414300P 2000-05-15 2000-05-15
US204143P 2000-05-15
PCT/US2001/015327 WO2001087307A2 (en) 2000-05-15 2001-05-10 Compositions and methods for the treatment of cancer

Publications (2)

Publication Number Publication Date
DE60118571D1 true DE60118571D1 (de) 2006-05-18
DE60118571T2 DE60118571T2 (de) 2007-02-01

Family

ID=22756804

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60118571T Expired - Lifetime DE60118571T2 (de) 2000-05-15 2001-05-10 Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten

Country Status (18)

Country Link
US (2) US7435726B2 (de)
EP (1) EP1307197B1 (de)
JP (1) JP5409981B2 (de)
KR (1) KR100790589B1 (de)
AR (1) AR029084A1 (de)
AT (1) ATE322266T1 (de)
AU (2) AU2001261474B2 (de)
BR (1) BR0110877A (de)
CA (1) CA2408707C (de)
DE (1) DE60118571T2 (de)
DK (1) DK1307197T3 (de)
ES (1) ES2258084T3 (de)
MX (1) MXPA02011218A (de)
NZ (1) NZ522767A (de)
PT (1) PT1307197E (de)
TW (1) TWI289449B (de)
WO (1) WO2001087307A2 (de)
ZA (1) ZA200209638B (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192360A1 (en) * 1999-04-14 2005-09-01 Li Chiang J. Method of treatment of pancreatic cancer
CA2430669C (en) * 2000-11-30 2011-06-14 The Children's Medical Center Corporation Synthesis of 3-amino-thalidomide and its enantiomers
US20020128228A1 (en) * 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer
US6440738B1 (en) * 2001-02-08 2002-08-27 Isis Pharmaceuticals, Inc. Antisense modulation of casein kinase 2-beta expression
EP1373494B1 (de) * 2001-03-29 2006-03-01 Topo Target A/S Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii
EP1435963A4 (de) * 2001-09-24 2005-10-26 Tosk Inc Cisplatin-formulierungen mit verringerter toxizität und verwendungsverfahren dafür
US20080075762A1 (en) * 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
RU2316326C2 (ru) * 2001-12-03 2008-02-10 Байер Фамэсьютиклс Копэрейшн Способ и композиция для лечения ракового заболевания, тозилат и фармацевтически приемлемые соли n-(4-хлор-3-(трифторметил)фенил)-n'-(4-(2-(n-метилкарбамоил)-4-пиридилокси)фенил)мочевины
AU2002366310A1 (en) * 2001-12-14 2003-06-30 Kyowa Engineering Co., Ltd. Method of inducing apoptosis and compositions therefor
BR0215650A (pt) * 2002-03-26 2005-01-04 Banyu Pharma Co Ltd Preparação combinada para a administração simultânea, separada, ou sequencial no tratamento do câncer, método para o tratamento do câncer, uso de pelo menos um composto, e, composição farmacêutica
CN1705439A (zh) * 2002-04-12 2005-12-07 细胞基因公司 干细胞和祖细胞分化的调节、鉴定及其应用
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CA2483340A1 (en) * 2002-04-24 2003-11-06 Research Development Foundation Synergistic effects of nuclear transcription factor nf-.kappa.b inhibitors and anti-neoplastic agents
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
EP2272513A1 (de) * 2002-05-17 2011-01-12 Celgene Corporation Pharmazeutische Zusammensetzungen zur Behandlung von Krebs
CN1668296A (zh) * 2002-05-17 2005-09-14 细胞基因公司 使用选择性细胞因子抑制性药物用于治疗和控制癌症和其它疾病的方法及组合物
US7196105B2 (en) * 2002-06-24 2007-03-27 Research Development Foundation Treatment of human multiple myeloma by curcumin
US20040034099A1 (en) * 2002-06-27 2004-02-19 Ramsey Beverly J. Pharmaceutical composition
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
EP1551385A4 (de) * 2002-10-15 2008-10-22 Celgene Corp Selektive cytokin-hemmenden arzneimittel zur behandlung von myelodysplastischem syndrom
KR20090048520A (ko) * 2002-11-06 2009-05-13 셀진 코포레이션 암 및 다른 질환의 치료 및 관리를 위한 선택적 시토킨 억제 약물의 사용 방법 및 그 조성물
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
BR0316002A (pt) * 2002-11-06 2005-09-13 Celgene Corp Métodos de tratar ou prevenir e controlar uma doença mieloproliferativa, de reduzir ou evitar de um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doença mieloproliferativa, composição farmacêutica e kit
EP1611137A1 (de) * 2003-03-31 2006-01-04 Pfizer Inc. Salze von tricyclischen poly(adp-ribose)polymerasen
CL2004001004A1 (es) * 2003-05-19 2005-03-18 Upjohn Co Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple.
US20070270504A1 (en) * 2003-06-20 2007-11-22 Avalon Pharmaceuticals, Inc. Identification of Therapeutic Agents Using Genetic Fingerprinting
US7264819B2 (en) * 2003-06-23 2007-09-04 Anticancer, Inc. Lyase treatment for P. carinii
WO2005020908A2 (en) * 2003-08-26 2005-03-10 Research Development Foundation Selective inhibitors of stat-3 activation and uses thereof
JP2007503475A (ja) 2003-08-26 2007-02-22 リサーチ ディベロップメント ファウンデーション 破骨細胞形成阻害剤およびその使用方法
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
JP2007510670A (ja) * 2003-11-06 2007-04-26 セルジーン・コーポレーション サリドマイドを用いた、癌、及び他の疾患を治療、及び管理する方法ならびに組成物
CN101966183A (zh) * 2003-12-02 2011-02-09 细胞基因公司 用于治疗和控制血红蛋白病和贫血病的方法和组合物
DE602004020506D1 (de) * 2003-12-12 2009-05-20 Quiral Quimica Do Brasil Verfahren zur herstellung von wasserfreien und hydratisierten pharmazeutischen wirkstoffen (apis); aus diesen hergestellte stabile pharmazeutische zusammensetzungen und anwendungen für diese zusammensetzungen
EP1722777A2 (de) * 2004-02-20 2006-11-22 Arqule, Inc. Verwendung von beta-lapachone zur behandlung von pangreaskarzinomen
EP2033639A2 (de) * 2004-02-20 2009-03-11 Arqule, Inc. Beta-Lapachon zur Behandlung von Dickdarmkrebs
EP2033640A2 (de) * 2004-02-20 2009-03-11 Arqule, Inc. Beta-Lapachon zur Behandlung von Lungenkrebs
EP1737493B1 (de) * 2004-02-25 2011-06-29 Dana-Farber Cancer Institute, Inc. Hemmer des insulinartigen wachstumsfaktor-rezeptors-1 zur hemmung von tumorzellwachstum
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
CA2561513C (en) 2004-03-29 2019-02-26 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20080199422A1 (en) * 2004-04-14 2008-08-21 Celgene Corporation Method for the Treatment of Myelodysplastic Syndromes Using 1-Oxo-2-(2,6-Dioxopiperidin-3-Yl-)-4-Methylisoindoline
EP1744748A4 (de) * 2004-04-14 2009-08-12 Celgene Corp Verfahren zur verwendung von selektiven zytokin-hemmenden arzneimitteln und diese enthaltende zusammensetzungen zur behandlung und versorgung von myelodysplastischen syndromen
KR20070008710A (ko) * 2004-04-27 2007-01-17 웰스테트 바이올로직스 코포레이션 바이러스 및 캄토테신을 이용한 암치료 방법
JP2007536221A (ja) * 2004-05-05 2007-12-13 セルジーン・コーポレーション 骨髄増殖性疾患を治療及び管理するための選択的サイトカイン阻害薬の使用方法及びそれを含む組成物
CA2565446A1 (en) * 2004-05-05 2005-12-01 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
NZ564954A (en) * 2005-06-14 2011-02-25 Protox Therapeutics Inc Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins
US20070066512A1 (en) * 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
WO2007089043A1 (ja) * 2006-02-03 2007-08-09 Takeda Pharmaceutical Company Limited リポソーム製剤
EP2019649A4 (de) * 2006-04-27 2012-09-19 Narmada R Shenoy Zusammensetzungen und verfahren zur behandlung oder vorbeugung von erkrankungen von körperdurchgangswegen
CL2007002218A1 (es) 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
EP2014651A1 (de) * 2007-07-12 2009-01-14 Exonhit Therapeutics SA Verbindungen und Verfahren zur Modulierung von Rho-GTPasen
WO2009020590A1 (en) * 2007-08-07 2009-02-12 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy
WO2009058394A1 (en) * 2007-11-01 2009-05-07 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
US20090192098A1 (en) * 2007-11-21 2009-07-30 Oxigene, Inc. Method for treating hematopoietic neoplasms
US20090137631A1 (en) * 2007-11-22 2009-05-28 National Yang-Ming University Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression
WO2010083436A1 (en) 2009-01-15 2010-07-22 Rutgers, The State University Of New Jersey Benzo [c] phenanthridines as antimicrobial agents
WO2010127307A1 (en) * 2009-04-30 2010-11-04 Rutgers, The State University Of New Jersey Antimicrobial agents
US8933096B2 (en) 2010-06-09 2015-01-13 Rugers, The State University of New Jersey Antimicrobial agents
WO2011163610A2 (en) 2010-06-25 2011-12-29 Rutgers, The State University Of New Jersey Antimicrobial agents
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
KR101369936B1 (ko) * 2011-12-28 2014-03-06 연세대학교 산학협력단 탈리도마이드를 포함하는 루프스 신염 치료용 약학 조성물
US9822108B2 (en) 2012-01-13 2017-11-21 Rutgers, The State University Of New Jersey Antimicrobial agents
WO2013142712A1 (en) 2012-03-21 2013-09-26 Rutgers, The State University Of New Jersey Antimicrobial agents
WO2014180882A2 (en) * 2013-05-07 2014-11-13 Universitat De Barcelona Treatment of brain metastasis from cancer
US20170080093A1 (en) * 2013-10-22 2017-03-23 Tyme, Inc. Tyrosine Derivatives And Compositions Comprising Them
US9458150B2 (en) 2013-11-08 2016-10-04 Rutgers, The State University Of New Jersey Antimicrobial agents
US10034872B2 (en) 2014-08-22 2018-07-31 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
US10001483B2 (en) 2015-06-26 2018-06-19 Celgene Corporation Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
US11419934B2 (en) 2015-08-18 2022-08-23 Oncotelic Therapeutics, Inc. Use of VDAS to enhance immunomodulating therapies against tumors
EP3419967A4 (de) 2016-02-25 2019-10-16 Taxis Pharmaceuticals, Inc. Synthetische verfahren und zwischenprodukte
CN115990157A (zh) 2016-04-29 2023-04-21 （株）娜迪安生物公司 用于预防或改善与抗癌药物治疗相关的副作用的药物组合物
SI3490560T1 (sl) 2016-07-29 2025-04-30 Janssen Pharmaceutica, N.V. Niraparib za uporabo pri metodi zdravljenja raka prostate
KR101851470B1 (ko) 2016-12-19 2018-06-11 한림대학교 산학협력단 퀘세틴이 함유된 유방암 예방 및 치료를 위한 약제학적 조성물
US10774093B2 (en) 2017-03-30 2020-09-15 Taxis Pharmaceuticals, Inc. Synthetic processes and synthetic intermediates
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5422344A (en) * 1990-05-08 1995-06-06 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Method of treating retroviral infections in mammals
AU1531492A (en) 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5643915A (en) 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
US5654312A (en) 1995-06-07 1997-08-05 Andrulis Pharmaceuticals Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
GB9523493D0 (en) * 1995-11-16 1996-01-17 British Biotech Pharm Preparation of allyl succinate derivatives and starting materials therefore

Also Published As

Publication number Publication date
JP5409981B2 (ja) 2014-02-05
JP2003533484A (ja) 2003-11-11
BR0110877A (pt) 2003-03-11
AU6147401A (en) 2001-11-26
MXPA02011218A (es) 2004-08-19
AR029084A1 (es) 2003-06-04
PT1307197E (pt) 2006-08-31
CA2408707C (en) 2010-04-13
TWI289449B (en) 2007-11-11
WO2001087307A3 (en) 2002-07-25
EP1307197B1 (de) 2006-04-05
US20050148524A1 (en) 2005-07-07
ATE322266T1 (de) 2006-04-15
DK1307197T3 (da) 2006-07-03
ES2258084T3 (es) 2006-08-16
HK1054502A1 (en) 2003-12-05
KR100790589B1 (ko) 2008-01-02
KR20030025922A (ko) 2003-03-29
AU2001261474B2 (en) 2006-03-09
EP1307197A2 (de) 2003-05-07
US7435726B2 (en) 2008-10-14
US20020035090A1 (en) 2002-03-21
DE60118571T2 (de) 2007-02-01
WO2001087307A2 (en) 2001-11-22
ZA200209638B (en) 2003-11-27
NZ522767A (en) 2004-07-30
CA2408707A1 (en) 2001-11-22

Similar Documents

Publication Publication Date Title
DE60118571D1 (de) Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten
DE60232251D1 (de) Pharmazeutische zusammensetzungen zur behandlung von asthma
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
DE60031127D1 (de) Nsaid und egfr kinase inhibitoren enthaltende pharmazeutische formulierung zur behandlung oder inhibierung von dickdarmpolypen und kolorektalem krebs
DE60035378D1 (de) Gerät zur Behandlung von Bandscheiben
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
ATE551100T1 (de) Pharmazeutische zusammensetzung zur behandlung von kardiovaskulären und cerebrovasakulären erkrankungen
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60108080D1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
DE602004022036D1 (de) Verfahren zur behandlung von atherosklerose, dyslipidämie und verwandten erkrankungen und pharmazeutische zusammensetzungen
EE200100717A (et) Indasooliühendid ja farmatseutilised kompositsioonid proteiini kinaaside inhibeerimiseks ja meetodid nende kasutamiseks
NO20024610L (no) Synergistiske metoder og blandinger for behandling av kreft
ATE468331T1 (de) Neue cyanopyridine-derivate zur behandlung von krebs und anderer erkrankungen
DE60227095D1 (de) Zusammensetzungen und verfahren zur behandlung von abgebundenem gips
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
IL230815A0 (en) Dictopiperazine compounds and pharmaceutical preparations containing them for the treatment of T-cell mediated diseases
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
ATE323661T1 (de) Behandlung von mineralischen stoffen
DE60019814D1 (de) Pharmazeutische kombinationen enthaltend tegaserod und omeprazole und ihre verwendung zur behandlung gastrointestinaler krankheiten
EP1085892A4 (de) Impfstrategie zur vorbeugung und behandlung von krebs
EP1255765A4 (de) Pharmazeutische zusammensetzung und therapeutische behandlung von rheumatischer arthritis
DE60030554D1 (de) Verwendungen von et743 zur behandlung von krebs
DE60229959D1 (de) Kombinationstherapie zur behandlung von krebs
EP1117395A4 (de) Verbindungen zur behandlung von östrogenabhängigen erkrankungen und deren herstellungs und verwendungsmethoden
DE60218375D1 (de) Pharmazeutische Zusammensetzung zur Behandlung gynäkologischer Erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8380 Miscellaneous part iii

Free format text: DIE ORTSANGABE BEIM ANMELDER WURDER GEAENDERT IN SUMMIT.